Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.